Document and Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 06, 2026 |
Jun. 30, 2025 |
|
| Document Information [Line Items] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | MCRB | ||
| Entity Registrant Name | Seres Therapeutics, Inc. | ||
| Entity Central Index Key | 0001609809 | ||
| Entity Current Reporting Status | Yes | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Shell Company | false | ||
| Entity File Number | 001-37465 | ||
| Entity Tax Identification Number | 27-4326290 | ||
| Entity Address, Address Line One | 101 Cambridgepark Drive | ||
| Entity Address, City or Town | Cambridge | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02140 | ||
| City Area Code | 617 | ||
| Local Phone Number | 945-9626 | ||
| Entity Public Float | $ 71,941,772 | ||
| Entity Common Stock Shares Outstanding | 9,586,298 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity Well Known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Interactive Data Current | Yes | ||
| Title of 12(b) Security | Common stock, par value $0.001 per share | ||
| Security Exchange Name | NASDAQ | ||
| Documents Incorporated by Reference | Portions of the registrant’s definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2025 are incorporated herein by reference in Part III. |
||
| Auditor Firm ID | 238 | ||
| Auditor Name | PricewaterhouseCoopers LLP | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Opinion [Text Block] | Opinions on the Financial Statements
We have audited the accompanying consolidated balance sheets of Seres Therapeutics, Inc. and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive income (loss), of stockholders' equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. |